Pipeline
Hematologic Malignancies Program
Our heme malignancies program is designed to treat patients who are undergoing a standard of care, allogeneic bone marrow transplantation (hematopoietic cell transplantation or HCT) for the treatment of acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplastic syndrome (MDS).
- Despite advances in transplant therapy, ~40% of patients undergoing HCT with reduced intensity conditioning relapse within two years, and patients that relapse face a poor prognosis with limited treatment options.
- We are developing TCR-Ts that recognize heme-specific antigens that are present on the patient’s, but not the donor’s, white blood cells. Our products are designed to eliminate residual cancer in the patient while sparing new, healthy blood cells that come from the donor’s stem cells.
- We are further expanding this program by developing additional TCR-T therapy candidates designed for patients with other HLA types.
Eliminate residual cancer by targeting blood-specific antigens present in the patient but not the donor
